Company news
Endonovo Therapeutics, Inc. news in 2022
Endonovo Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Endonovo Announces Advancement of International “Go to Market” Initiative
December 19, 2022
Endonovo Announces Plans for Spin-off of Medical IP and Assets
December 15, 2022
Endonovo Launches Telehealth Initiative
December 13, 2022
Endonovo Names Ira Weisberg President to Guide Global Medical Expansion
November 30, 2022
Endonovo announces plan to explore strategic alternatives for its SofPulse® medical device assets
November 17, 2022
Endonovo Therapeutics Issues Corporate Update
November 7, 2022
Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company
September 27, 2022
Endonovo Therapeutics Releases Comparative Analysis Demonstrating
July 28, 2022
Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management
July 21, 2022
Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company
June 9, 2022
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products
April 25, 2022
$5 Million Common Stock Offering for Endonovo Therapeutics Designed to Advance SofPulse® Process for Medical Reimbursement
April 11, 2022
Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo
March 1, 2022
Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance
February 16, 2022